Stock listing

Egetis Therapeutics Ab

Selected listing: A1JH3B · LSX · EUR · DE

Egetis Therapeutics Ab (LS Exchange: A1JH3B), Health Technology. Latest release Sep 29, 2026: Egetis Therapeutics Announces U.S. FDA Approval of EMCITATE(R)…

A1JH3B:LSXEURDEUpdated October 3, 2026

Ticker: LS Exchange: A1JH3B
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: LS Exchange
Currency: EUR

Latest news from Egetis Therapeutics Ab

Egetis Therapeutics Announces U.S. FDA Approval of EMCITATE(R) (tiratricol) for Patients with MCT8 Deficiency

September 29, 2026

Egetis Therapeutics Announces U.S. FDA Approval of EMCITATE® (tiratricol) for Patients with MCT8 Deficiency

September 28, 2026

Egetis Therapeutics to Participate in Upcoming Investor Conferences in September

September 3, 2026

Egetis' Interim report Q2 2026

August 21, 2026

Invitation to Presentation of Egetis’ Q2 2026 Report on August 21, 2026

August 7, 2026

All Egetis Therapeutics Ab news →

Events

Replays

Egetis Therapeutics AB (publ) (EGTX) Q2 2026 Earnings Call
Fri, Aug 21, 2026 · 08:00 AM ET
Watch
Egetis Therapeutics AB (publ) (EGTX) Q1 2026 Earnings Call
Wed, Apr 29, 2026 · 04:00 AM ET
Watch

Research Egetis Therapeutics Ab

Egetis Therapeutics Ab company profile

View the public company page for Egetis Therapeutics Ab on 6ix.

Egetis Therapeutics Ab news

Read company news and market updates connected to Egetis Therapeutics Ab.

Egetis Therapeutics Ab investor events

Find investor webinars, events, and replay context for Egetis Therapeutics Ab.